Testing different dose levels of a new immunotherapy called CT-202 to assess its safety in people with nectin-4-positive triple-negative breast cancer, bowel cancer, or urothelial cancer.
Inclusion Criteria:
Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies
Participants with measurable disease per RECIST 1.1
ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks
Participants have adequate organ function.
Exclusion Criteria:
History of severe skin toxicity
Uncontrolled significant active infection or any medical or other condition that in the opinion of the Investigator would preclude the participant's participation in the study.
Concurrent participation in another investigational clinical trial.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
Please share the referral to Dr Andrew Hill at Tasman Health care if you think it is eligible.
